IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1101-1125 out of 1240.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

Public Release: 15-May-2014
PLOS ONE
New tool to grow cancer cells streamlines laboratory research
A new technique that allows the growth of both normal and cancer cells and keeps them alive indefinitely is transforming and expediting basic cancer research. 'We've had a glimpse of how these cells can provide an amazing advance in human cancer clinical research in preliminary work, and now we demonstrate how incredibly useful they are in laboratory cancer research,' says the lead researcher.
National Institutes of Health

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 15-May-2014
Journal of the National Cancer Institute
Tumor cells in the blood may indicate poor prognosis in early breast cancer
Tumor cells in bone marrow of early breast cancer patients predict a higher risk of relapse as well as poorer survival, but bone marrow biopsy is an invasive and painful procedure. Now, it may be possible to identify tumor cells in a routine blood sample and use them as prognostic markers, according to a study published May 15 in the Journal of the National Cancer Institute.

Contact: Zachary Rathner
Zachary.Rathner@oup.com
919-677-2697
Oxford University Press USA

Public Release: 15-May-2014
Cell Reports
First test of pluripotent stem cell therapy in monkeys is a success
Researchers have shown for the first time in an animal that is more closely related to humans that it is possible to make new bone from stem-cell-like induced pluripotent stem cells (iPSCs) made from an individual animal's own skin cells. The study in monkeys also shows that there is some risk that those iPSCs could seed tumors, but that unfortunate outcome appears to be less likely than studies in immune-compromised mice would suggest.

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Public Release: 15-May-2014
Nature Structural & Molecular Biology
Detailed studies reveal how key cancer-fighting protein is held in check
St. Jude Children's Research Hospital scientists have mapped the structural details of how p53 attaches to its regulatory protein, called BCL-xL, in the cell. The protein p53 is a key activator of the cell's protective machinery against genetic damage, such as the mutations that drive cancer cells' explosive growth.
National Institutes of Health, NIH/National Cancer Institute, American-Lebanese-Syrian Associated Charities

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital

Public Release: 15-May-2014
Cancer Cell
Genetic tracking identifies cancer stem cells in human patients
The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer -- cancer stem cells. The international research team, led by scientists at the University of Oxford and the Karolinska Institutet in Sweden, studied a group of patients with myelodysplastic syndromes -- a malignant blood condition which frequently develops into acute myeloid leukemia. The researchers say their findings offer conclusive evidence for the existence of cancer stem cells.
Leukemia and Lymphoma Society, Leukaemia and Lymphoma Research, and others

Contact: University of Oxford
news.office@admin.ox.ac.uk
44-186-528-0530
University of Oxford

Public Release: 15-May-2014
Journal of Pain and Symptom Management
Next frontier: How can modern medicine help dying patients achieve a 'good' death?
The overall quality of death of cancer patients who die in an urban Canadian setting with ready access to palliative care was found to be good to excellent in the large majority of cases, helping to dispel the myth that marked suffering at the end of life is inevitable.

Contact: Alex Radkewycz
Alexandra.Radkewycz@uhn.ca
416-340-3895
University Health Network

Public Release: 15-May-2014
ASCO 50th Annual Meeting
Getting chemo first may help in rectal cancer
A new phase II study to be presented at the annual meeting of the American Society for Clinical Oncology finds that if chemotherapy is offered before radiation and surgery, more patients will be able to tolerate it and receive a full regimen of treatment.
Brown University

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University

Public Release: 15-May-2014
Anticancer Research
Cancer's potential on-off switch
A team of Boston University School of Medicine researchers have proposed that an 'on and off' epigenetic switch could be a common mechanism behind the development of different types of cancer. Epigenetics is the phenomena whereby genetically identical cells express their genes differently, resulting in different physical traits. Researchers from the Boston University Cancer Center recently published two articles about this in Anticancer Research and Epigenomics.

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center

Public Release: 15-May-2014
Proceedings of the National Academy of Sciences
Learning from sharks
Genetically engineered antibodies are deployed successfully in cancer diagnostics and therapy. Therapeutic antibodies against Alzheimer's disease and multiple sclerosis are currently under development. An important criterion when designing suitable antibody fragments is their stability. Comparing the antibodies of sharks with those of humans, a team of researchers at the Technische Universitaet Muenchen and the Helmholtz Zentrum Muenchen discovered stabilizing mechanisms that can also be applied to optimize custom-tailored antibodies for medical applications.
German Research Foundation, European Molecular Biology Organization, Swedish Research Council, National Institute of Health, German National Academic Foundation

Contact: Dr. Andreas Battenberg
battenberg@zv.tum.de
49-892-891-0510
Technische Universitaet Muenchen

Public Release: 14-May-2014
ASCO 50th Annual Meeting
Cancer patient demands rarely lead to unnecessary tests and treatments
Despite claims suggesting otherwise, inappropriate cancer patient demands are few and very rarely lead to unnecessary tests and treatments from their health care providers, according to new results from a study that will be presented by researchers in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania during the annual meeting of the American Society of Clinical Oncology in Chicago in early June.

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-301-5221
University of Pennsylvania School of Medicine

Public Release: 14-May-2014
New England Journal of Medicine
Researchers propose treating prison population to fight US hepatitis C epidemic
Nearly four million Americans may be infected with the hepatitis C virus, with many people unaware of their status. The virus can take decades to make those infected ill with cirrhosis, cancer or liver failure. Three researchers argue in the May 15 issue of the New England Journal of Medicine that America's oversized prison population provides a critical opportunity to tackle the US hepatitis C epidemic. One in six prisoners is infected with the virus.

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside

Public Release: 14-May-2014
ASCO 50th Annual Meeting
Large panel genetic testing produces more questions than answers in breast cancer
While large genetic testing panels promise to uncover clues about patients' DNA, a team of researchers from Penn Medicine's Abramson Cancer Center has found that those powerful tests tend to produce more questions than they answer.

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-301-5221
University of Pennsylvania School of Medicine

Public Release: 14-May-2014
ASCO 50th Annual Meeting
New way to predict response to chemo in triple-negative breast cancer
Researchers from University Hospitals Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer. The data are being presented at the ASCO Annual Meeting.

Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Case Medical Center

Public Release: 14-May-2014
Journal of the National Cancer Institute
Study shows breastfeeding, birth control may reduce ovarian cancer risk in women with BRCA mutations
Breastfeeding, tubal ligation -- also known as having one's 'tubes tied' -- and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from a team at the University of Pennsylvania's Basser Research Center for BRCA and the Abramson Cancer Center. The findings, a meta-analysis of 44 existing peer-reviewed studies, are published in the Journal of the National Cancer Institute.

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine

Public Release: 14-May-2014
Journal of Visualized Experiments
SapC-DOPS technology may help with imaging brain tumors, research shows
The Cincinnati Cancer Center and University of Cincinnati Cancer Institute research studies published in an April online issue of the Journal of Magnetic Resonance Imaging and a May issue of the Journal of Visualized Experiments reveal possibly new ways to image glioblastoma multiforme tumors -- a form of brain tumor -- using the SapC-DOPS technology.
Mayfield Education and Research Foundation, New Drug State Key Project, NIH/National Cancer Institute

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center

Public Release: 14-May-2014
ASCO 50th Annual Meeting
Phase I data suggest PLX3397 is a potential therapy for patients with advanced PVNS
New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.
Plexxikon

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3956
Memorial Sloan-Kettering Cancer Center

Public Release: 13-May-2014
Nature Communications
Male infertility: It's all about the package
Infertility is generally thought of as a woman's problem. In fact, more than 3 million men across America also experience it. Today, researchers from Cold Spring Harbor Laboratory (CSHL) describe a key event during sperm development that is essential for male fertility. A team led by CSHL professor Alea Mills explains how a protein controls DNA packaging to protect a man's genetic information.
NIH/National Cancer Institute

Contact: Jaclyn Jansen
jjansen@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory

Public Release: 13-May-2014
Molecular Cancer Therapeutics
Novel target found for chemotherapy-resistant leukemia cells
Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles

Public Release: 13-May-2014
Cancer
Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment
Treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies such as surgery or radiation therapy does not help them live longer.
NIH/National Institutes of Diabetes and Digestive and Kidney Diseases, American Cancer Society

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-794-2262
University of California - Los Angeles Health Sciences

Public Release: 13-May-2014
European Molecular Biology Organization Journal
Researchers identify link between colon cancer and metabolism
Rather than the typical series of oxidative steps that take place in the citric acid cycle, cancer cells metabolize sugar via the glycolytic pathway irrespective of whether oxygen is present or not. In The EMBO Journal, researchers in the United States report that the reason for this difference in colon cancer is changes in the Wnt signaling pathway, an essential communication pathway operating in these tumors.

Contact: Barry Whyte
barry.whyte@embo.org
EMBO

Public Release: 13-May-2014
Cancer Cell
Identified 2 new genes involved in the more aggressive prostate cancer
A study by the Columbia University Nova York, in collaboration with the Catalan Institute of Oncology , Belvitge Biomedical Research Institute has identified two new genes that lead to more aggressive forms of prostate cancer. The work done by Alvaro Aytes under the direction of Cory Abate-Shen , director of the Herbert Irving Comprehensive Cancer Center of the Columbia University, has been published in the latest issue of Cancer Cell.

Contact: Arantxa Mena
amena@idibell.cat
0034-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 13-May-2014
Stem Cell Symposium
Cancer stem cells under the microscope at Albert Einstein College of Medicine symposium
Healthy stem cells work to restore or repair the body's tissues, but cancer stem cells have a more nefarious mission: to spawn malignant tumors. Cancer stem cells were discovered a decade ago, but their origins and identity remain largely unknown.

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine

Public Release: 13-May-2014
JAMA
Study findings question benefit of additional imaging before cancer surgery
This study is the largest, based on high-quality imaging and reading of scans, to understand the role of PET-CT in selecting the best colorectal cancer candidates whose cancer has spread to the liver for surgery.
Ontario Ministry of Health and Long-Term Care

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University

Public Release: 13-May-2014
International Journal of Cancer
New agent may enhance effectiveness of radiotherapy
Scientists from The University of Manchester -- part of the Manchester Cancer Research Centre -- have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth. There is increasing interest in using the body's own immune system to attack tumor cells -- a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Contact: Ali Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 13-May-2014
Orthopedics
Professional surfer back in the water after successful surgery to treat rare bone cancer
When professional surfer Richie Lovett began experiencing hip pain at 31, he attributed it to his athletic lifestyle. But after months of discomfort and preliminary tests, the Australian native learned the pain was caused by a cancerous tumor in his femur or thigh bone.

Contact: Cara Martinez
cara.martinez@cshs.org
310-423-7798
Cedars-Sinai Medical Center

Showing releases 1101-1125 out of 1240.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

  Search News Releases

     

 

EurekAlert!